The currently used injectable hormonal contraceptive contains: A. Long acting progestin B. Long acting estrogen C. Both long acting estrogen and progestin D. Chorionic gonadotropin

The currently used injectable hormonal contraceptive contains:
A. Long acting progestin
B. Long acting estrogen
C. Both long acting estrogen and progestin
D. Chorionic gonadotropin
by

1 Answer

Answer :

A. Long acting progestin
by

Related questions

The most popular form of hormonal contraception is: A. Combined estrogen + progestin oral pill B. Phased estrogen + progestin oral pill C. Postcoital estrogen + progestin pill D. Depot progestin injection

Description : The most popular form of hormonal contraception is: A. Combined estrogen + progestin oral pill B. Phased estrogen + progestin oral pill C. Postcoital estrogen + progestin pill D. Depot progestin injection

Last Answer : A. Combined estrogen + progestin oral pill

Placenta secretes all of the following except (A) FSH (B) Progesterone (C) Estrogen (D) Chorionic gonadotropin HORMONE METABOLISM 225

Description : Placenta secretes all of the following except (A) FSH (B) Progesterone (C) Estrogen (D) Chorionic gonadotropin HORMONE METABOLISM 225

Last Answer : Answer : A

A hormone used for detection of pregnancy is (A) Estrogen (B) Progesterone (C) Oxytocin (D) Chorionic gonadotropin

Description : A hormone used for detection of pregnancy is (A) Estrogen (B) Progesterone (C) Oxytocin (D) Chorionic gonadotropin

Last Answer : Answer : D

Which of the following hormones is not a secretion product of human placenta? (a) Human chorionic gonadotropin (b) Prolactin (c) Estrogen (d) Progesterone

Description : Which of the following hormones is not a secretion product of human placenta? (a) Human chorionic gonadotropin (b) Prolactin (c) Estrogen (d) Progesterone

Last Answer : (b) Prolactin

The main function of mammalian corpus luteum is to produce (a) estrogen only (b) progesterone (c) human chorionic gonadotropin (d) relaxin only.

Description : The main function of mammalian corpus luteum is to produce (a) estrogen only (b) progesterone (c) human chorionic gonadotropin (d) relaxin only.

Last Answer : (b) progesterone

A progestin and an estrogen are combined in oral contraceptive pill because: A. The estrogen blocks the side effects of the progestin B. The progestin blocks the side effects of the estrogen C. Both synergise to suppress ovulation D. Both synergise to produce hostile cervical mucus

Description : A progestin and an estrogen are combined in oral contraceptive pill because: A. The estrogen blocks the side effects of the progestin B. The progestin blocks the side effects of the estrogen C. Both synergise to suppress ovulation D. Both synergise to produce hostile cervical mucus

Last Answer : C. Both synergise to suppress ovulation

Addition of a progestin for 10-12 days every month to cyclic estrogen replacement therapy during menopause is recommended because the progestin: A. Prevents osteoporosis B. Prevents irregular bleeding C. Blocks increased risk of endometrial carcinoma D. Both ‘B’ and ‘C’ are correct

Description : Addition of a progestin for 10-12 days every month to cyclic estrogen replacement therapy during menopause is recommended because the progestin: A. Prevents osteoporosis B. Prevents irregular bleeding C. Blocks increased risk of endometrial carcinoma D. Both ‘B’ and ‘C’ are correct

Last Answer : D. Both ‘B’ and ‘C’ are correct

Select the compound which used for hormone replacement therapy in postmenopausal women serves the purpose of both estrogen and progestin with weak androgenic activity: A. Tibolone B. Mestranol C. Desogestrel D. Gestodene

Description : Select the compound which used for hormone replacement therapy in postmenopausal women serves the purpose of both estrogen and progestin with weak androgenic activity: A. Tibolone B. Mestranol C. Desogestrel D. Gestodene

Last Answer : A. Tibolone

The following contraceptive acts primarily by interfering with implantation of blastocyst: A. Gossypol B. Centchroman C. Combined estrogen-progestin pill D. Phased pill

Description : The following contraceptive acts primarily by interfering with implantation of blastocyst: A. Gossypol B. Centchroman C. Combined estrogen-progestin pill D. Phased pill

Last Answer : B. Centchroman

On stoppage of the combined estrogen-progestin contraceptive pill, fertility returns after: A. 1–2 months B. 4–6 months C. 6–12 months D. Uncertain period

Description : On stoppage of the combined estrogen-progestin contraceptive pill, fertility returns after: A. 1–2 months B. 4–6 months C. 6–12 months D. Uncertain period

Last Answer : A. 1–2 months

The primary mechanism of action of the combined estrogen-progestin oral contraceptive pill is: A. Production of cervical mucus hostile to sperm penetration B. Suppression of FSH and LH release C. Making endometrium unsuitable for implantation D. Enhancing uterine contractions to dislodge the fertilized ovum

Description : The primary mechanism of action of the combined estrogen-progestin oral contraceptive pill is: A. Production of cervical mucus hostile to sperm penetration B. Suppression of FSH and ... Making endometrium unsuitable for implantation D. Enhancing uterine contractions to dislodge the fertilized ovum

Last Answer : B. Suppression of FSH and LH release

The purpose/purposes served by the progestin component of the combined estrogen + progestin contraceptive pill is/are: A. Suppression of ovulation B. Prompt bleeding at the end of the course C. Blockade of increased risk of endometrial carcinoma D. All of the above

Description : The purpose/purposes served by the progestin component of the combined estrogen + progestin contraceptive pill is/are: A. Suppression of ovulation B. Prompt bleeding at the end of the course C. Blockade of increased risk of endometrial carcinoma D. All of the above

Last Answer : D. All of the above

Select the progestin preparation for coadministration with estrogen for hormone replacement therapy that does not counteract the beneficial effect of the latter on lipid profile due to lack of androgenic activity: A. Micronized oral progesterone B. Norethindrone C. Lynestrenol D. Medroxyprogesterone acetate (p. 281-282)

Description : Select the progestin preparation for coadministration with estrogen for hormone replacement therapy that does not counteract the beneficial effect of the latter on lipid profile due to lack of ... oral progesterone B. Norethindrone C. Lynestrenol D. Medroxyprogesterone acetate (p. 281-282)

Last Answer : Select the indication for which a progestin is used alone without combining with an estrogen: A. Threatened abortion B. Dysfunctional uterine bleeding C. Hormone replacement therapy D. Premenstrual tension

Addition of a progestin for 10-12 days each month to estrogen replacement therapy in menopausal women is recommended because the progestin: A. Blocks the increased risk of myocardial infarction due to estrogen B. Blocks the increased risk of endometrial carcinoma due to estrogen C. Reverses vulval atrophy occurring in postmenopausal women D. Enhances the metabolic benefits of estrogen treatment

Description : Addition of a progestin for 10-12 days each month to estrogen replacement therapy in menopausal women is recommended because the progestin: A. Blocks the increased risk of myocardial ... vulval atrophy occurring in postmenopausal women D. Enhances the metabolic benefits of estrogen treatment

Last Answer : The estrogen commonly used for hormone replacement therapy in menopausal women is: A. Ethinylestradiol B. Estradiol benzoate C. Diethylstilbestrol D. Conjugated estrogens

In which of the following conditions estrogen is not the primary drug but is added to progestin as adjuvant: A. Dysfunctional uterine bleeding B. Menopausal syndrome C. Osteoporosis D. Atrophic vaginitis

Description : In which of the following conditions estrogen is not the primary drug but is added to progestin as adjuvant: A. Dysfunctional uterine bleeding B. Menopausal syndrome C. Osteoporosis D. Atrophic vaginitis

Last Answer : A. Dysfunctional uterine bleeding

The progestin used in combined oral contraceptive pill is a 19-nortestosterone derivative because: A. They have potent antiovulatory action of their own B. They do not produce any metabolic effects C. They produce fewer side effects D. They are longer acting

Description : The progestin used in combined oral contraceptive pill is a 19-nortestosterone derivative because: A. They have potent antiovulatory action of their own B. They do not produce any metabolic effects C. They produce fewer side effects D. They are longer acting

Last Answer : A. They have potent antiovulatory action of their own

16.5 Octreotide is a long acting synthetic analogue of: A. Prolactin B. Growth hormone C. Somatostatin D. Gonadotropin releasing hormone

Description : 16.5 Octreotide is a long acting synthetic analogue of: A. Prolactin B. Growth hormone C. Somatostatin D. Gonadotropin releasing hormone

Last Answer : D. All of the above

The most common and important undesirable effect of injectable contraceptive depot medroxyprogesterone acetate is: A. Nausea and vomiting B. Disruption of cyclic menstrual bleeding C. Venous thrombosis D. Hypertension

Description : The most common and important undesirable effect of injectable contraceptive depot medroxyprogesterone acetate is: A. Nausea and vomiting B. Disruption of cyclic menstrual bleeding C. Venous thrombosis D. Hypertension

Last Answer : B. Disruption of cyclic menstrual bleeding

What is human chorionic gonadotropin (hCG)? -Biology

Description : What is human chorionic gonadotropin (hCG)? -Biology

Last Answer : answer:

What is human chorionic gonadotropin (hCG)? -Biology

Description : What is human chorionic gonadotropin (hCG)? -Biology

Last Answer : answer:

Placental hormone called chorionic gonadotropin (HCG) which stimulates secretion of progesterone by the ovary during pregnancy is

Description : Placental hormone called chorionic gonadotropin (HCG) which stimulates secretion of progesterone by the ovary during pregnancy is

Last Answer : Placental hormone called chorionic gonadotropin (HCG) which stimulates secretion of progesterone by the ovary during ... amine D. Both (1) and (2)

Total number of amino acids in human chorionic gonadotropin is (A) 53 (B) 92 (C) 145 (D) 237

Description : Total number of amino acids in human chorionic gonadotropin is (A) 53 (B) 92 (C) 145 (D) 237

Last Answer : Answer : D

.The fetal ejection reflex in humans triggers the release of (a) oxytocin from fetal pituitary (b) human chorionic gonadotropin (hCG) from placenta (c) human placental lactogen (hPL) from placenta (d) oxytocin from maternal pituitary.

Description : .The fetal ejection reflex in humans triggers the release of (a) oxytocin from fetal pituitary (b) human chorionic gonadotropin (hCG) from placenta (c) human placental lactogen (hPL) from placenta (d) oxytocin from maternal pituitary.

Last Answer : (d) oxytocin from maternal pituitary.

Match the following columns and select the correct option. Column-I Column-II (A) Placenta (i) Androgens (B) Zona pellucida (ii) Human Chorionic Gonadotropin (HCG) (C) Bulbourethral glands (iii) Layer of the ovum (D) Leydig cells (iv) Lubrication of the penis (A) (B) (C) (D) (a) (iv) (iii) (i) (ii) (b) (i) (iv) (ii) (iii) (c) (iii) (ii) (iv) (i) (d) (ii) (iii) (iv) (i)

Description : Match the following columns and select the correct option. Column-I Column-II (A) Placenta (i) Androgens (B) Zona pellucida (ii) Human Chorionic Gonadotropin (HCG) (C) Bulbourethral glands (iii) Layer of the ovum (D) Leydig cells (iv) ... (ii) (iii) (c) (iii) (ii) (iv) (i) (d) (ii) (iii) (iv) (i)

Last Answer : (d) (ii) (iii) (iv) (i)

Choose the selective estrogen receptor modulator that is useful in dysfunctional uterine bleeding by acting as estrogen antagonist in endometrium, but does not alter vaginal epithelium or cervical mucus: A. Ormeloxifene B. Tamoxifen C. Centchroman D. Danazol

Description : Choose the selective estrogen receptor modulator that is useful in dysfunctional uterine bleeding by acting as estrogen antagonist in endometrium, but does not alter vaginal epithelium or cervical mucus: A. Ormeloxifene B. Tamoxifen C. Centchroman D. Danazol

Last Answer : . Ormeloxifen

When both ovaries are removed from rat then which hormone is decreased in blood? (a) Oxytocin (b) Prolactin (c) Estrogen (d) Gonadotropin releasing factor

Description : When both ovaries are removed from rat then which hormone is decreased in blood? (a) Oxytocin (b) Prolactin (c) Estrogen (d) Gonadotropin releasing factor

Last Answer : (c) Estrogen

Select the correct option describing gonadotropin activity in a normal pregnant female. (a) High level of FSH and LH stimulates the thickening of endometrium. (b) High level of FSH and LH facilitates implantation of the embryo. (c) High level of hCG stimulates the synthesis of estrogen and progesterone. (d) High level of hCG stimulates the thickening of endometrium.

Description : Select the correct option describing gonadotropin activity in a normal pregnant female. (a) High level of FSH and LH stimulates the thickening of endometrium. (b) High level of FSH and LH ... synthesis of estrogen and progesterone. (d) High level of hCG stimulates the thickening of endometrium.

Last Answer : (c) High level of hCG stimulates the synthesis of estrogen and progesterone.

In a normal pregnant woman, the amount of total gonadotropin activity was assessed. The result expected was (1) High level of circulating HCG to stimulate estrogen and progesterone synthesis (2) High level of circulating FSH and LH in the uterus to stimulate implantation of the embryo (3) High level of circulating HCG to stimulate endometrial thickening (4) High levels of FSH and LH in uterus to stimulate endometrial thickening

Description : In a normal pregnant woman, the amount of total gonadotropin activity was assessed. The result expected was (1) High level of circulating HCG to stimulate estrogen and progesterone synthesis (2) ... endometrial thickening (4) High levels of FSH and LH in uterus to stimulate endometrial thickening

Last Answer : (1) High level of circulating HCG to stimulate estrogen and progesterone synthesis

Side effects of cyclic progestin therapy include the following except: A. Headache B. Gastroesophageal reflux C. Breast dyscomfort D. Irregular bleeding

Description : Side effects of cyclic progestin therapy include the following except: A. Headache B. Gastroesophageal reflux C. Breast dyscomfort D. Irregular bleeding

Last Answer : D. Irregular bleeding

Which of the following statements most closely reflects the current status of estrogens in postmenopausal women: A. Estrogens should be prescribed routinely to all menopausal women B. Estrogens should be prescribed when menopausal symptoms are severe C. Estrogens should be prescribed only when there is radiological evidence of osteoporosis D. Estrogens should be prescribed along with a progestin after considering risk:benefit ratio in individual patients

Description : Which of the following statements most closely reflects the current status of estrogens in postmenopausal women: A. Estrogens should be prescribed routinely to all menopausal women B. ... should be prescribed along with a progestin after considering risk:benefit ratio in individual patients

Last Answer : . Estrogens should be prescribed along with a progestin after considering risk:benefit ratio in individual patients

Chlorpromazine therapy increases the secretion of the following hormone: A. Prolactin B. Gonadotropin C. Corticotropin D. Antidiuretic hormone

Description : Chlorpromazine therapy increases the secretion of the following hormone: A. Prolactin B. Gonadotropin C. Corticotropin D. Antidiuretic hormone

Last Answer : A. Prolactin

Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Description : Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial stimulation ... release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Last Answer : C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks

16.17 Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Description : 16.17 Superactive GnRH agonists cause: A. Initial as well as sustained release of gonadotropins B. Initial inhibition followed by stimulation of gonadotropin release after 1-2 weeks C. Initial ... release after 1-2 weeks D. Initial as well as sustained inhibition of gonadotropin release

Last Answer : C. Initial stimulation followed by inhibition of gonadotropin release after 1-2 weeks

16.15 The hypothalamic gonadotropin releasing hormone (GnRH) is: A. A single peptide B. A mixture of two distinct peptides FSH-RH and LH-RH C. A mixture of several peptides D. Dopamine

Description : 16.15 The hypothalamic gonadotropin releasing hormone (GnRH) is: A. A single peptide B. A mixture of two distinct peptides FSH-RH and LH-RH C. A mixture of several peptides D. Dopamine

Last Answer : A. A single peptide

The following hypothalamic regulatory hormone is not a peptide: A. Growth hormone release inhibitory hormone B. Prolactin release inhibitory hormone C. Gonadotropin releasing hormone D. Corticotropin releasing hormone (

Description : The following hypothalamic regulatory hormone is not a peptide: A. Growth hormone release inhibitory hormone B. Prolactin release inhibitory hormone C. Gonadotropin releasing hormone D. Corticotropin releasing hormone (

Last Answer : B. Prolactin release inhibitory hormone

What is true of docetaxel: A. It is used as a reserve drug for refractory breast and ovarian cancer B. It is a selective estrogen receptor modulator used for breast cancer C. It is effective only in estrogen receptor positive breast cancer D. Both 'B' and 'C' are correct

Description : What is true of docetaxel: A. It is used as a reserve drug for refractory breast and ovarian cancer B. It is a selective estrogen receptor modulator used for breast cancer C. It is effective only in estrogen receptor positive breast cancer D. Both 'B' and 'C' are correct

Last Answer : A. It is used as a reserve drug for refractory breast and ovarian cancer

The distinctive features of desogestrel include the following except: A. It is a prodrug B. It has both strong progestational and strong antiovulatory activities C. It has additional androgenic acitivity D. It does not counteract the beneficial effect of estrogen on lipid profile

Description : The distinctive features of desogestrel include the following except: A. It is a prodrug B. It has both strong progestational and strong antiovulatory activities C. It has additional androgenic acitivity D. It does not counteract the beneficial effect of estrogen on lipid profile

Last Answer : C. It has additional androgenic acitivity

he distinctive features of desogestrel include the following except: A. It is a prodrug B. It has both strong progestational and strong antiovulatory activities C. It has additional androgenic acitivity D. It does not counteract the beneficial effect of estrogen on lipid profile

Description : he distinctive features of desogestrel include the following except: A. It is a prodrug B. It has both strong progestational and strong antiovulatory activities C. It has additional androgenic acitivity D. It does not counteract the beneficial effect of estrogen on lipid profile

Last Answer : C. It has additional androgenic acitivity

The following is true of raloxifene except: A. It acts as an estrogen agonist in bone B. It exerts estrogen antagonistic action on endometrium C. It increases risk of developing breast cancer D. It can induce/aggravate menopausal hot flushes

Description : The following is true of raloxifene except: A. It acts as an estrogen agonist in bone B. It exerts estrogen antagonistic action on endometrium C. It increases risk of developing breast cancer D. It can induce/aggravate menopausal hot flushes

Last Answer : C. It has additional androgenic acitivity

What is true of tamoxifen: A. It can induce endometrial proliferation in postmenopausal women B. It exerts antiestrogenic activity in bone C. It raises LDL-cholesterol levels D. It is ineffective in estrogen receptor-negative breast cancer

Description : What is true of tamoxifen: A. It can induce endometrial proliferation in postmenopausal women B. It exerts antiestrogenic activity in bone C. It raises LDL-cholesterol levels D. It is ineffective in estrogen receptor-negative breast cancer

Last Answer : A. It can induce endometrial proliferation in postmenopausal women

Which of the following is a selective estrogen receptor modulator that improves bone mineral density in postmenopausal women: A. Clomiphene citrate B. Raloxifene C. Ormeloxifene D. Alendronate

Description : Which of the following is a selective estrogen receptor modulator that improves bone mineral density in postmenopausal women: A. Clomiphene citrate B. Raloxifene C. Ormeloxifene D. Alendronate

Last Answer : B. Raloxifene

Estrogen replacement therapy for postmenopausal women is contraindicated in subjects with: A. Leg vein thrombosis B. Undiagnosed vaginal bleeding C. Migraine D. All of the above

Description : Estrogen replacement therapy for postmenopausal women is contraindicated in subjects with: A. Leg vein thrombosis B. Undiagnosed vaginal bleeding C. Migraine D. All of the above

Last Answer : D. All of the above

Select the correct statement about tibolone: A. It is an antiestrogen used for palliative treatment of carcinoma breast B. It is an estrogenic + progestational steroid used for hormone replacement therapy in postmenopausal women C. It is an antiandrogen used for male pattern baldness D. It is a nonsteroidal estrogen used topically for senile vaginitis

Description : Select the correct statement about tibolone: A. It is an antiestrogen used for palliative treatment of carcinoma breast B. It is an estrogenic + progestational steroid used for hormone replacement ... for male pattern baldness D. It is a nonsteroidal estrogen used topically for senile vaginitis

Last Answer : B. It is an estrogenic + progestational steroid used for hormone replacement therapy in postmenopausal women

The daily dose of estrogen for hormone replacement therapy in postmenopausal women is: A. Same as for contraception B. Higher than that for contraception C. Lower than that for contraception D. Variable depending on the age of the woman

Description : The daily dose of estrogen for hormone replacement therapy in postmenopausal women is: A. Same as for contraception B. Higher than that for contraception C. Lower than that for contraception D. Variable depending on the age of the woman

Last Answer : C. Lower than that for contraception

The estrogen commonly used for hormone replacement therapy in menopausal women is: A. Ethinylestradiol B. Estradiol benzoate C. Diethylstilbestrol D. Conjugated estrogens

Description : The estrogen commonly used for hormone replacement therapy in menopausal women is: A. Ethinylestradiol B. Estradiol benzoate C. Diethylstilbestrol D. Conjugated estrogens

Last Answer : D. Conjugated estrogen

Estrogen therapy can worsen the following associated conditions except: A. Migraine B. Cholelithiasis C. Acne vulgaris D. Endometriosis

Description : Estrogen therapy can worsen the following associated conditions except: A. Migraine B. Cholelithiasis C. Acne vulgaris D. Endometriosis

Last Answer : C. Acne vulgaris

Transdermal estradiol differs from oral estrogen therapy in that it: A. Causes less induction of hepatic synthesis of clotting factors B. Does not inhibit FSH secretion C. Does not affect vaginal cytology D. All of the above are correct

Description : Transdermal estradiol differs from oral estrogen therapy in that it: A. Causes less induction of hepatic synthesis of clotting factors B. Does not inhibit FSH secretion C. Does not affect vaginal cytology D. All of the above are correct

Last Answer : A. Causes less induction of hepatic synthesis of clotting factors

Estrogen therapy in postmenopausal women has been implicated in increasing the risk of the following disorders except: A. Gall stones B. Osteoporosis C. Endometrial carcinoma D. Breast cancer

Description : Estrogen therapy in postmenopausal women has been implicated in increasing the risk of the following disorders except: A. Gall stones B. Osteoporosis C. Endometrial carcinoma D. Breast cancer

Last Answer : B. Osteoporosis

Choose the correct statement about nateglinide: A. It is a long acting oral hypoglycaemic drug B. Taken just before a meal, it limits postprandial hyperglycaemia in type 2 diabetes mellitus C. It lowers blood glucose in both type 1 and type 2 diabetes mellitus D. It acts by opening K+ channels in myocytes and adipocytes

Description : Choose the correct statement about nateglinide: A. It is a long acting oral hypoglycaemic drug B. Taken just before a meal, it limits postprandial hyperglycaemia in type 2 diabetes mellitus C. It lowers ... 1 and type 2 diabetes mellitus D. It acts by opening K+ channels in myocytes and adipocytes

Last Answer : B. Taken just before a meal, it limits postprandial hyperglycaemia in type 2 diabetes mellitus

What is true about use of amphotericin B in kala azar: A. It is currently the drug of choice B. It is more effective than ketoconazole C. It is indicated only in cases not responding to sodium stibogluconate D. Both 'B' and 'C' are correct

Description : What is true about use of amphotericin B in kala azar: A. It is currently the drug of choice B. It is more effective than ketoconazole C. It is indicated only in cases not responding to sodium stibogluconate D. Both 'B' and 'C' are correct

Last Answer : D. Both 'B' and 'C' are correct